Treatment with atenolol prevents progression of microalbuminuria in Type I diabetic patients

Summary

Nine patients with Type I diabetes mellitus, diastolic blood pressure of 90 to 100 mmHg and persistent microalbuminuria of 230 μg/min were treated with 50 to 100 mg atenolol daily for 3 years in an uncontrolled pilot study to assess the effect of long-term reduction of blood pressure on microalbuminuria. Treatment with atenolol prevented progression of microalbuminuria with a median (range) urinay albumin excretion rate before treatment of 74 (33 to 196) μg/min and 50 (5 to 123) μg/min after 3 years of therapy (p<0.05). Blood pressure was significantly reduced from 156 (121 to 187) mmHg systolic and 95 (90 to 100) mmHg diastolic before treatment to 143 (112 to 168) mmHg systolic (p<0.04) and 82 (66 to 84) mmHg diastolic p<0.0003) at 3 years. Measurements of renal function and diabetic control remained unchanged throughout the study period. These results suggest that early and prolonged use of antihypertensive therapy is beneficial in slowing down progression of microalbuminuria.

Key Words::

• Atenolol
• adrenergic beta receptor blockaders
• albuminuria
• diabetes mellitus
• insulin-dependent